They further constructed acquired sunitinib-resistant RCC cell lines and xenograft mouse models with Caki-1 and 786-O, and found that ABCB-1 inhibition with elacridar, combined with sunitinib, reverses sunitinib resistance development in vitro and in vivo. This evidence concerns the gene ABCB1 and renal cell carcinoma.